Main Menu

Our Work

Swanston v. TAP Pharmaceutical Products

In Swanston v. TAP Pharmaceutical Products, provided expert testimony on issues of predominance and feasible damages methodologies on behalf of a joint defense group of leading pharmaceutical manufacturers opposing class certification. Analyzed reimbursements for both self-administered and physician-administered drugs made by patients covered by government-sponsored health insurance programs including Medicare, Medicaid, and TRICARE, patients covered by private health insurance programs, and patients without insurance. Submitted written report.

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.